Antitumor activity of XR5944, a novel and potent topoisomerase poison

Anti-Cancer Drugs

Volumn 12, Issue 4, 2001, Pages 359-367

  Stewart, Alistair J ^a   Mistry, Prakash ^a   Dangerfield, Wendy ^a   Bootle, Douglas ^a   Baker, Mark ^a   Kofler, Bettina ^a   Okiji, Sade ^a   Baguley, Bruce C ^b   Denny, William A ^b   Charlton, Peter A ^a  

^a Cantab Pharmaceuticals Ltd   (United Kingdom)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Anti cancer; Poison; Topoisomerase I; Topoisomerase II; Xenografts

Indexed keywords

6 [2 (DIMETHYLAMINO)ETHYLAMINO] 3 HYDROXY 7H INDENO[2,1 C]QUINOLIN 7 ONE; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; GYRASE INHIBITOR; PACLITAXEL; TOPOTECAN; UNCLASSIFIED DRUG; XR 5944;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG TOLERANCE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMINOQUINOLINES; ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COLONIC NEOPLASMS; DNA; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; HUMANS; INDENES; INHIBITORY CONCENTRATION 50; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; ISOENZYMES; LUNG NEOPLASMS; MICE; MICE, NUDE; PHENAZINES; REMISSION INDUCTION; TOPOTECAN; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035017573     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200104000-00009     Document Type: Article

References (23)

1. 1. Wang JC. DNA topoisomerases. Annu Rev Biochem 1996; 65: 635-92.
2. 2. Hande KR. Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim Biophys Acta 1998; 1400: 173-84.
3. 3. Dancey J, Eisenhauer EA. Current perspectives on camptothecins in cancer treatment. Br J Cancer 1996; 74: 327-38.
4. 4. Finlay GJ, Riou J-F, Baguley BC. From Amsacrine to DACA (N - [2 - (dimethylamino) ethyl] acridine - 4 - carboxamide): selectivity for topoisomerase I and II among acridine derivatives. Eur J Cancer 1996; 32A: 708-14.
5. 5. Riou J-F, Fosse P, Nguyen CH, et al. Intoplicine (RP 60475) and its derivatives, a new class of antitumour agents inhibiting both topoisomerase I and II activities. Cancer Res 1993; 53: 5987-93.
6. 6. Hill BT, Barret JM, Perrin D, et al. Mechanism of action of F11782, a novel catalytic inhibitor of topoisomerase I and II. Proc Am Ass Cancer Res 1999; 755: 114.
7. 7. Utsugi T, Aoyagi K, Asao T, et al. Antitumour activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerase I and II. Jpn J Cancer Res 1997; 88: 992-1002.
8. 8. Beck WT, Cirtain MC, Danks MK, et al. Pharmacological, molecular and cytogenetic analysis of 'atypical' multidrug-resistance human leukaemic cells. Cancer Res 1987; 47: 5455-60.
9. 9. Tan KB, Mattem MR, Eng W-K, McCabe FL, Johnson RK, Non-productive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 1989; 81: 1732-35.
10. 10. Tanizawa A, Pommiery Y. Topoisomerase-1 alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. Cancer Res 1992; 52: 1848-54.
11. 11. Kaufmann SH. Cell death induced by topoisomerase-targeted drugs: more questions than answers. Biochim Biophys Acta 1998; 1400: 195-212.
12. 12. Haldane A, Holdaway KM, Finlay G, Baguley BC. Cytokinetic differences in the action of N-[2-(dimethyl-amino)ethyl]acridine-4-carboxamide as compared with that of amsacrine and doxorubicin. Cancer Chemother Pharmacol 1993; 32: 463-70.
13. 13. Holden JA, Rolfson DH, Wittwer CT. Human DNA topoisomerase II: evaluation of enzyme activity in normal and neoplastic tissues. Biochemistry 1990; 29: 2127-34.
14. 14. Twentyman PR, Fox NE, Wright KA, Blechen NM. Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells. Br J Cancer 1986; 53: 529-37.
15. 15. Dale IL, Tuffley W, Callaghan R, et al. Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative. Br J Cancer 1998; 78: 885-92.
16. 16. Finlay GJ, Marshall E, Matthews JH, Paull KD, Baguley BC. In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance. Cancer Chemother Pharmacol 1993; 31: 401-6.
17. 17. Mistry P, Plumb J, Eccles S, et al. In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance. Br J Cancer 1999; 79: 1672-8.
18. 18. Aoyagi Y, Kobunai T, Utsugi T, Oh-hara T, Yamada Y. In vitro antitumour activity of TAS-103, a novel quinoline derivative that targets topoisomerase I and II. Jpn J Cancer Res 1999; 90: 578-87.
19. 19. Vasey PA, Kaye SB. Combination inhibition of topoisomerase I and II - is this a worthwhile/feasible strategy? Br J Cancer 1997; 76: 1395-7.
20. 20. Byl JA, Fortune JM, Burden DA, et al. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement. Biochemistry 1999; 38: 15573-9.
21. 21. Fortune JM, Velea L, Graves DE, Utsugi T, Yamada Y, Osheroff N. DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition. Biochemistry 1999; 38: 15580-6.
22. 22. Stewart AJ, Dangerfield W, Lancashire H, et al. Antitumour activity of XR5944, a novel topoisomerase inhibitor. Clin Cancer Res 1999; 5(suppl): 3864.
23. 23. Bailly C, Brana M, Waring MJ. Sequence selective intercalation of antitumour bis-naphthalimides into DNA. Evidence for an approach via the major groove. Eur J Biochem 1996; 240: 195-208.